These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 31066991

  • 1. Nebivolol in the treatment of arterial hypertension.
    Olawi N, Krüger M, Grimm D, Infanger M, Wehland M.
    Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):189-201. PubMed ID: 31066991
    [Abstract] [Full Text] [Related]

  • 2. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE, DiGennaro F, Giani JF, Dominici FP.
    Vasc Health Risk Manag; 2012 Sep; 8():151-60. PubMed ID: 22454559
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients.
    Zanchetti A.
    Blood Press Suppl; 2004 Oct; 1():17-32. PubMed ID: 15587108
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker.
    Gao Y, Vanhoutte PM.
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):16-21. PubMed ID: 21283024
    [Abstract] [Full Text] [Related]

  • 9. Third-generation beta-adrenoceptor antagonists in the treatment of hypertension and heart failure.
    Fisker FY, Grimm D, Wehland M.
    Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):5-14. PubMed ID: 25732141
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.
    Marketou M, Gupta Y, Jain S, Vardas P.
    Curr Hypertens Rep; 2017 Mar; 19(3):22. PubMed ID: 28283926
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men.
    Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH.
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):327-31. PubMed ID: 17324145
    [Abstract] [Full Text] [Related]

  • 14. Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension.
    Sander GE, Giles TD.
    Expert Opin Pharmacother; 2015 Apr; 16(5):763-70. PubMed ID: 25747524
    [Abstract] [Full Text] [Related]

  • 15. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study.
    Vitale C, Marazzi G, Iellamo F, Spoletini I, Dall'Armi V, Fini M, Volterrani M.
    Int J Cardiol; 2012 Mar 08; 155(2):279-84. PubMed ID: 22078979
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nebivolol: third-generation beta-blockade.
    de Boer RA, Voors AA, van Veldhuisen DJ.
    Expert Opin Pharmacother; 2007 Jul 08; 8(10):1539-50. PubMed ID: 17661735
    [Abstract] [Full Text] [Related]

  • 19. Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension.
    Li B, Zhang Q, Zhang H, Wang C, Xiu R.
    Biosci Rep; 2020 May 29; 40(5):. PubMed ID: 32342981
    [Abstract] [Full Text] [Related]

  • 20. A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension.
    Cicero AFG, Kuwabara M, Borghi C.
    Drugs; 2018 Nov 29; 78(17):1783-1790. PubMed ID: 30426333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.